Potential of FTIR-Spectroscopy for Drugs Screening against <i>Helicobacter pylori</i>

<i>Helicobacter pylori</i> colonizes the human stomach of half of the world’s population. The infection if not treated, persists through life, leading to chronic gastric inflammation, that may progress to severe diseases as peptic ulcer, gastric adenocarcinoma, and mucosa-associated lymp...

Full description

Bibliographic Details
Main Authors: Pedro S. Sampaio, Cecília R. C. Calado
Format: Article
Language:English
Published: MDPI AG 2020-12-01
Series:Antibiotics
Subjects:
Online Access:https://www.mdpi.com/2079-6382/9/12/897
_version_ 1827700192085803008
author Pedro S. Sampaio
Cecília R. C. Calado
author_facet Pedro S. Sampaio
Cecília R. C. Calado
author_sort Pedro S. Sampaio
collection DOAJ
description <i>Helicobacter pylori</i> colonizes the human stomach of half of the world’s population. The infection if not treated, persists through life, leading to chronic gastric inflammation, that may progress to severe diseases as peptic ulcer, gastric adenocarcinoma, and mucosa-associated lymphoid tissue lymphoma. The first line of treatment, based on 7 to 21 days of two antibiotics associated with a proton pump inhibitor, is, however, already failing most due to patient non-compliance that leads to antibiotic resistance. It is, therefore, urgent to screen for new and more efficient antimicrobials against this bacterium. In this work, Fourier Transform Infrared (FTIR) spectroscopy was evaluated to screen new drugs against <i>H. pylori,</i> in rapid (between 1 to 6 h), and high-throughput mode and based on a microliter volume processes in relation to the agar dilution method. The reference <i>H. pylori</i> strains 26,695 and J99, were evaluated against a peptide-based antimicrobial and the clinical antibiotic clarithromycin, respectively. After optimization of the assay conditions, as the composition of the incubation mixture, the time of incubation, and spectral pre-processing, it was possible to reproducibly observe the effect of the drug on the bacterial molecular fingerprint as pointed by the spectra principal component analysis. The spectra, obtained from both reference strains, after its incubation with drugs concentrations lower than the MIC, presented peak ratios statistically different (<i>p</i> < 0.05) in relation to the bacteria incubated with drugs concentrations equal or higher to the MIC. It was possible to develop a partial least square regression model, enabling to predict from spectra of both bacteria strains, the drug concentration on the assay, with a high correlation coefficient between predicted and experimental data (0.91) and root square error of 40% of the minimum inhibitory concentration. All this points to the high potential of the technique for drug screening against this fastidious growth bacterium.
first_indexed 2024-03-10T14:07:49Z
format Article
id doaj.art-767873ed825748fe968d8c9103f0178c
institution Directory Open Access Journal
issn 2079-6382
language English
last_indexed 2024-03-10T14:07:49Z
publishDate 2020-12-01
publisher MDPI AG
record_format Article
series Antibiotics
spelling doaj.art-767873ed825748fe968d8c9103f0178c2023-11-21T00:29:57ZengMDPI AGAntibiotics2079-63822020-12-0191289710.3390/antibiotics9120897Potential of FTIR-Spectroscopy for Drugs Screening against <i>Helicobacter pylori</i>Pedro S. Sampaio0Cecília R. C. Calado1DREAMS—Interdisciplinary Center for Development and Research in Environment, Applied Management and Space, Faculty of Engineering, Lusophone University of Humanities and Technologies, Campo Grande, 376, 1749‑024 Lisbon, PortugalCIMOSM—Centro de Investigação em Modelação e Optimização de Sistemas Multifuncionais, ISEL—Instituto Superior de Engenharia de Lisboa, Instituto Politécnico de Lisboa, R. Conselheiro Emídio Navarro 1, 1959-007 Lisboa, Portugal<i>Helicobacter pylori</i> colonizes the human stomach of half of the world’s population. The infection if not treated, persists through life, leading to chronic gastric inflammation, that may progress to severe diseases as peptic ulcer, gastric adenocarcinoma, and mucosa-associated lymphoid tissue lymphoma. The first line of treatment, based on 7 to 21 days of two antibiotics associated with a proton pump inhibitor, is, however, already failing most due to patient non-compliance that leads to antibiotic resistance. It is, therefore, urgent to screen for new and more efficient antimicrobials against this bacterium. In this work, Fourier Transform Infrared (FTIR) spectroscopy was evaluated to screen new drugs against <i>H. pylori,</i> in rapid (between 1 to 6 h), and high-throughput mode and based on a microliter volume processes in relation to the agar dilution method. The reference <i>H. pylori</i> strains 26,695 and J99, were evaluated against a peptide-based antimicrobial and the clinical antibiotic clarithromycin, respectively. After optimization of the assay conditions, as the composition of the incubation mixture, the time of incubation, and spectral pre-processing, it was possible to reproducibly observe the effect of the drug on the bacterial molecular fingerprint as pointed by the spectra principal component analysis. The spectra, obtained from both reference strains, after its incubation with drugs concentrations lower than the MIC, presented peak ratios statistically different (<i>p</i> < 0.05) in relation to the bacteria incubated with drugs concentrations equal or higher to the MIC. It was possible to develop a partial least square regression model, enabling to predict from spectra of both bacteria strains, the drug concentration on the assay, with a high correlation coefficient between predicted and experimental data (0.91) and root square error of 40% of the minimum inhibitory concentration. All this points to the high potential of the technique for drug screening against this fastidious growth bacterium.https://www.mdpi.com/2079-6382/9/12/897drugs screeningFourier-transform infrared (FTIR) spectroscopy<i>Helicobacter pylori</i>high-throughput screening
spellingShingle Pedro S. Sampaio
Cecília R. C. Calado
Potential of FTIR-Spectroscopy for Drugs Screening against <i>Helicobacter pylori</i>
Antibiotics
drugs screening
Fourier-transform infrared (FTIR) spectroscopy
<i>Helicobacter pylori</i>
high-throughput screening
title Potential of FTIR-Spectroscopy for Drugs Screening against <i>Helicobacter pylori</i>
title_full Potential of FTIR-Spectroscopy for Drugs Screening against <i>Helicobacter pylori</i>
title_fullStr Potential of FTIR-Spectroscopy for Drugs Screening against <i>Helicobacter pylori</i>
title_full_unstemmed Potential of FTIR-Spectroscopy for Drugs Screening against <i>Helicobacter pylori</i>
title_short Potential of FTIR-Spectroscopy for Drugs Screening against <i>Helicobacter pylori</i>
title_sort potential of ftir spectroscopy for drugs screening against i helicobacter pylori i
topic drugs screening
Fourier-transform infrared (FTIR) spectroscopy
<i>Helicobacter pylori</i>
high-throughput screening
url https://www.mdpi.com/2079-6382/9/12/897
work_keys_str_mv AT pedrossampaio potentialofftirspectroscopyfordrugsscreeningagainstihelicobacterpylorii
AT ceciliarccalado potentialofftirspectroscopyfordrugsscreeningagainstihelicobacterpylorii